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AllostericThe cysteine protease brucipain is an important drug target in the protozoan Trypanosoma brucei, the causa-
tive agent of both Human African trypanosomiasis and Animal African trypanosomiasis. Brucipain is closely
related to mammalian cathepsin L and currently used as a framework for the development of inhibitors
that display anti-parasitic activity. We show that recombinant brucipain lacking the C-terminal extension un-
dergoes inhibition by the substrate benzyloxycarbonyl-FR-7-amino-4-methylcoumarin at concentrations
above the Km, but not by benzyloxycarbonyl-VLR-7-amino-4-methylcoumarin. The allosteric modulation
exerted by the substrate is controlled by temperature, being apparent at 25 °C but concealed at 37 °C. The be-
havior of the enzyme in vitro can be explained by discrete conformational changes caused by the shifts in
temperature that render it less susceptible to substrate inhibition. Enzyme inhibition by the di-peptydyl sub-
strate impaired the degradation of human ﬁbrinogen at 25 °C, but not at 37 °C. We also found that heparan
sulfate acts as a natural allosteric modulator of the enzyme through interactions that prevent substrate inhi-
bition. We propose that brucipain shifts between an active and an inactive form as a result of temperature-
dependent allosteric regulation.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The parasitic protozoa Trypanosoma brucei and its sub-species are
the causative agents of Human African trypanosomiasis (HAT) and of
Nagana disease in cattle in Sub-Saharan Africa. HAT is a major cause
of death and disability in Africa and the incidence of the disease in-
creased between 1991 and 1998, and has been decreasing steadily
ever since [1]. The parasite is transmitted to humans and animals by
the bite of the blood sucking tsetse ﬂy, and at the late stage of the dis-
ease, the infected individuals develop severe meningoencephalitis as
a result of the penetration of the parasite into the central nervous sys-
tem [2]. Nagana disease kills about 1 million cattle each year, result-
ing in large economic costs. Both in humans and animals, untreated
cases are eventually fatal [3,4]. Chemotherapy currently relies on
four drugs, two of which are used for the treatment of the late (en-
cephalitic) stage of the disease. Those drugs display low-efﬁcacy, var-
iable degrees of toxicity, and are expensive to produce and
administer, leading to an urgent need to develop new therapies
and/or strategies to ﬁnd suitable new drug targets [5].lamido-(4-guanidino)butane);
amino-4-methylcoumarin hy-
–leucine–arginine-7-amino-4-
hreitol
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evier OA license.Cysteine proteases of the Clan CA, family C1 papain-like family
(CPs) of T. brucei have emerged as attractive drug targets based on ev-
idence that their activities are crucial for parasite survival and/or vir-
ulence [3,6–8]. T. brucei contains two C1 family CPs; a cathepsin L-like
protease, named rhodesain, brucipain or trypanopain [9–11], which is
encoded by a family of eleven nearly identical gene copies and a sin-
gle cathepsin B-like protease gene [11,12]. Rhodesain has a central
domain with similarity to mammalian cathepsin L and a 110 amino
acids C-terminal extension of unknown function which is not essen-
tial for enzymatic activity [11,13]. The diverse nomenclature assigned
to the cathepsin L-like protease of T. brucei refers essentially to the
same enzymatic activity. Recently, a unambiguous nomenclature sys-
tem was proposed where the ﬁrst letter of the genus followed by the
ﬁrst two letters of the species (all in italics), to indicate the organism,
is placed in front of a four letter code (i.e. CATL), to indicate the en-
zyme in question [3]. TbbCATL (for T. brucei brucei CATL) is expressed
at all parasite life-cycle stages and located in the lysosome, where it is
implicated in the degradation of proteins [11]. Recently, we reported
that the activity of TbrCATL correlates with the ability of T. brucei rho-
desiense to traverse the blood brain barrier [14], and subsequent work
revealed that partial knock-down of this protease in T. brucei pro-
longed the survival of infected mice [15]. Recombinant TbrCATL has
been used as a frame for the screening of potent synthetic inhibitors
[16–18], and is a target in the continuous search for reﬁned inhibitor
structures and improved modes of drug delivery to intracellular or-
ganelles of the parasite [19–22]. Recently, the crystal structure of
TbrCATL was solved in complex with either the K11007 or K1102
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tures of the T. cruzi CATL (cruzain) and TbrCATL are super imposable
and highly conserved, sharing important structural features necessary
for inhibitor biding.
The extensive studies of TbrCATL inhibition contrast with the few
reports on the enzyme substrate speciﬁcity. A limited analysis of the
TbrCATL speciﬁcity using di-peptidyl substrates revealed equivalent
preference for substrates containing either Phe or Leu at the P2 posi-
tion [11], and a subsequent screen of peptide libraries extended this
analysis to the P3 site [25]. The relative contribution of changes in
the P2/P3 sites for the synthesis of more potent inhibitors to TbrCATL
was recently evaluated reporting favorable effects of P2/P3 modiﬁca-
tion on protease inhibition [17,18].
Here, we report that recombinant TbbCATL undergoes inhibition
by a di-peptidyl substrate commonly used in inhibitor screening
assays, a characteristic previously described for TcrCATL [26,27].
This behavior has not been previously acknowledged for TbbCATL
and might have inﬂuenced the inhibition studies performed so far.
Substrate inhibition is temperature-dependent as it is obscured by in-
creases in temperature to 37 °C, most likely associated with transitory
conformational changes of the enzyme. We describe that both en-
zyme activity and susceptibility to substrate inhibition are modulated
by heparan sulfate.
2. Materials and methods
2.1. Recombinant brucipain
Recombinant brucipain (TbbCATL) was expressed in Escherichia
coli (M15) in its truncated form, lacking the C-terminal extension.
Brieﬂy, the region of the TbbCATL gene spanning the pro and central
domains was ampliﬁed by Polymerase Chain Reaction using the
high ﬁdelity Phusion polymerase and the primers to the prodomain
(forward 5′GGGGATCCTGCCTTGCNNCNGTNGCNCT), containing a
BamHI site (italic) and to the central domain (reverse 5′
GGGGTACCGCCNCNNACAACNGC) containing a KpnI site (italic). The
amino acid deduced sequence of TbbCATL is 99% identical to that of
rodhesain (TbrCATL); Val16 is missing in TbbCATL used in this
work. Probrucipain (TbbCATL) was cloned in the pQE30 (QIAGen) ex-
pression plasmid into BamHI and KpnI and expressed as a fusion pro-
tein with a poli-histidine tag by the induction of E. coli cultures grown
LB, 40 μg/mL kanamycin, 50 μg/mL ampicillin with 1 mM IPTG for 4 h,
at 37 °C. Inclusion bodies were denatured in 100 mM NaH2PO4,
10 mM Tris, 8 M urea, pH 8, before puriﬁcation in Ni-NTA resins. Pu-
riﬁed probrucipain was refolded by incubation in 100 mM Tris–HCl,
pH 8, 1 mM EDTA, 250 mM L-Arginine, 20% glycerol, overnight at
4 °C, was subsequently dialyzed to and activated in 50 mM NaOAc,
pH 5.5, 200 mMNaCl, 5 mM EDTA, 1 mMDTT (dithiothreitol). Mature
enzyme was afﬁnity puriﬁed in a Thiopropyl sepharose 6B column as
previously described, subsequently dialyzed to 10 mM Tris–HCl, pH 8,
0.1 mM EDTA, 25 mM L-Arginine, 2% glycerol, by ultra-ﬁltration using
an Amicon device, and kept at 4 °C until used [28].
2.2. Parasite culture and lysates
The bloodstream form (BSF) of T. brucei rhodesiense IL1852 [14]
were cultivated in HMI-9 medium (Invitrogen) supplemented with
10% inactivated fetal bovine serum (FBS) (Biosera-South America)
and 10% of serum plus supplement (SAFC Bioscience—USA), at 37 °C
in a 5% CO2 humidiﬁed incubator. 106 BSF were washed once in me-
dium without serum and resuspended in 20 mM Na2HPO4, pH 7.2,
150 mM NaCl (PBS), 1% Igepal CA-630 (Sigma-Aldrich-USA) an incu-
bated on ice, for 30 min. The samples were centrifuged at 13,000× g,
for 10 min and the soluble fraction was recovered. The lysates were
tested for protease activity in 50 mM Na2HPO4, 100 mM NaCl, 5 mM
EDTA pH 6.5, 2.5 mM DTT using 3 μM of benzyloxycarbonyl-phenyl-alanyl-arginine-7-amino-4-methylcoumarin (Z-FR-MCA) as a sub-
strate. E-64 (L-trans-Epoxysuccinylleucylamido-(4-guanidino)bu-
tane) (Sigma) was added to the samples at 10 μM to verify the
activity of papain-like cysteine proteases.2.3. Kinetic measurements
Puriﬁed TbbCATL (0.25 nM) was assayed in 50 mM Na2HPO4, pH
6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM DTT. The enzyme was pre-
activated in the reaction buffer for 10 min at room temperature before
the assays. Enzyme activity was followed by the release of the ﬂuoro-
genic group from Z-FR-MCA or benzyloxycarbonyl-valine–leucine–
arginine-7-amino-4-methylcoumarin (Z-VLR-MCA) (Sigma), in
continuous assays, at 380 nm excitation and 440 nm emission, in a
Hitachi f-4500 spectroﬂuorometer. Enzyme activity was assayed at in-
creasing substrate concentration ([S]) at 25 °C or 37 °C and the initial
velocities were calculated by linear regression of the substrate hydroly-
sis plots, using at least 300 points. For the determination of the kinetic
parameters (Km, Ki and Vmax), the curves from the plots of initial veloc-
ity versus substrate concentration were ﬁtted to the appropriate equa-
tions (substrate inhibition: Y=Vmax*[S]/(Km+[S]*(1+[S]/Ki)); or
Michaelis–Menten: Y=Vmax*[S]/(Km+[S]) by non-linear regression
using the Prism program. Only the best calculated curves showing R2
above 0.9 were considered. The kcat values were calculated according
to: kcat=Vmax/[E]. The enzyme concentration ([E]) was determined
by active-site titration using E-64 according to Ref. [29]. Brieﬂy, the ti-
tration was performed upon incubation of the enzyme with various in-
hibitor concentrations at room temperature for 10 min. The remaining
activity was measured upon the addition of 5 μM Z-FR-MCA. The en-
zyme concentration was calculated from the equation of the linear re-
gression of the V0 versus [E64] considering Y=0. All assays were
performed in duplicates at least two independent times.2.4. Kinetics in the presence of heparan sulfate
Heparan sulfate puriﬁed from bovine pancreas (Sigma) was dilut-
ed in 20 mM Na2HPO4, 150 mM NaCl, pH 7.2 at 2 mg/mL. For the
binding assay, TbbCATL was incubated with the indicated concentra-
tions of heparan sulfate (25–1000 ng/mL) for 15 min at room temper-
ature in assay buffer and subsequently activated with 2.5 mM DTT for
10 min before the assay. The measurement of enzyme activity was
initiated by addition of 50 μM Z-FR-MCA and the initial velocities
were calculated as described above. The dissociation constant was de-
termined from the best calculated curve, by ﬁtting the experimental
data of the V0 versus [HS4] plot, using the equation for one site-
speciﬁc binding (Y=Bmax*X/(Kd+X) in the Prism program.2.5. Intrinsic ﬂuorescence spectroscopy
Intrinsic ﬂuorescence spectra of recombinant TbbCATL (1.2 nM)
were recorded in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM
EDTA, using 3 mL single-use acrylic cuvettes, in 1 mL solution, at
25 °C or 37 °C, in a Hitachi F-4500 ﬂuorimeter. The sample was incu-
bated in buffer at 25 °C for 10 min, excited at 280 nm or at 295 nm
and the emission spectrum over the range of 300–390 nm was
recorded. The cuvette with the sample was subsequently incubated
at 37 °C for 30 min, and the spectrum was recorded at 37 °C, as
above. Afterwards the cuvette was incubated at 4 °C for 30 min (in
order to accelerate temperature-dependent conformational changes),
followed by incubation at 25 °C for additional 30 min, before record-
ing the spectrum at 25 °C. The experiment was performed three inde-
pendent times. The areas of the emission spectra at each condition
were determined and the average values±SEM were plotted.
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Stock TbbCATL was activated in 50 mM Na2HPO4, pH 6.5, 100 mM
NaCl, 5 mM EDTA, 5 mM DTT for 10 min at room temperature and di-
luted to 0.3 nM, in the same buffer without DTT for the proteolysis
assay. The reaction was carried out in 50 mM Na2HPO4, pH 6.5,
100 mM NaCl, 5 mM EDTA, 0.5 mM DTT and human ﬁbrinogen
(Sigma, European Union) at 750 μg/mL, for 15 min, at 25 °C or 37 °C.
For the assays at 37 °C, stock enzyme was incubated at 37 °C for 1 h,
before activation in buffer supplemented with 5 mM DTT for
10 min, as above, followed by dilution and addition of ﬁbrinogen.
Where indicated in the ﬁgures, Z-VLR-MCA or Z-FR-MCA were
added at 60 μM, immediately before the addition of ﬁbrinogen. The
reactions were stopped by addition of SDS-PAGE sample buffer
(62.5 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-β-
mercaptoethanol, bromophenolblue), boiled for 5 min, resolved in
11% SDS-PAGE gels and Coomassie stained. Each experiment was per-
formed in duplicate, two independent times. The de-stained gels
were scanned and the relative densitometries of the alpha, beta and
gamma ﬁbrinogen chains were determined using the ImageJ pro-
gram. The averages of the areas were calculated using the values of
the duplicates and plotted with ±SD.
3. Results
3.1. Temperature-dependent substrate inhibition of TbbCATL
The three-dimensional structure of TbbCATL conﬁrmed that it can
be highly superimposed with that of TcrCATL, which has been exten-
sively characterized biochemically [23,24]. We and others have
shown that TcrCATL undergoes substrate inhibition by the di-
peptidyl substrate Z-FR-MCA at concentrations higher than 10 μM,
when assayed at 25 °C [26,27]. Given the striking structural similarity
between the two proteases, we set out to investigate if some of the
properties displayed by TcrCATL are shared by TbbCATL. To this end,
we performed kinetic assays with TbbCATL using Z-FR-MCA, a pre-
ferred substrate for mammalian cathepsin L [30]. We found that,
when assayed at 25 °C, the enzymatic activity of TbbCATL is signiﬁ-
cantly reduced at substrate concentrations >10 μM, similarly to
TcrCATL [26,27]. The calculated progress curves showing enzyme in-
hibition as a function of substrate concentration are shown in
Fig. 1A. The activity of TbbCATL decayed at substrate concentrations
higher than 10 μM, in a concentration-dependent manner. We ob-
served an immediate decay in the rate of hydrolysis when the sub-
strate concentrations were raised from 10 μM to 20 μM, suggesting
that the interaction of substrate molecules with regions other than
the active site have a signiﬁcant and rapid effect on enzyme function.
This was consistently observed using different stocks of Z-FR-MCA,
and different batches of puriﬁed enzyme, arguing against an artifact
due to contaminants with inhibitory action against the protease.
The average kinetic parameters extracted from the ﬁtted curves are
listed in Table 1. Considering that TbbCATL has a single active site,
as determined by the tri-dimensional structure, a second substrate
molecule presumably binds to an allosteric site, diminishing enzyme
activity.
Similarly to TcrCATL, we observed that the activity of TbbCATL is
unaltered at saturation concentrations of substrate when the protease
is assayed at 37 °C (Fig. 1B). At this temperature, the enzyme kinetics
obeyed a typical Michaelis–Menten curve, reaching Vmax at approxi-
mately 10 μM of the substrate. There were no signiﬁcant changes in
the Km values for this substrate at the two temperatures, however,
there was a two-fold increase in the kcat value at 37 °C (Table 1).
The absence of substrate inhibition at 37 °C was only achieved after
pre-incubation of the protease at this temperature for at least
15 min, suggesting that slow molecular events must occur before
the enzyme is no longer susceptible to modulation of its activity athigh substrate concentrations. This characteristic was previously ob-
served with TcrCATL [26]. Importantly, when TbbCATL is ﬁrst assayed
at 37 °C, and subsequently incubated at 25 °C, it becomes again sus-
ceptible to substrate inhibition (data not shown), arguing against
proteolytic processing of the enzyme or other permanent structural
modiﬁcations resulting from the incubation at 37 °C. Next, we veriﬁed
if this behavior was observed during the hydrolysis of a structurally
similar substrate, Z-VLR-MCA, that lacks a bulky aromatic ring at the
P2 position. The activity of TbbCATL was unaffected by this substrate
when assayed at 25 °C, even at concentrations as high as 500 μM
(Fig. 1C) and the enzyme displayed virtually identical kinetics when
assayed at 37 °C (Fig. 1D). TbbCATL showed about 26-fold difference
in the Km value for the abovementioned substrate as compared to Z-
FR-MCA (Table 1), which is in agreement with previous data showing
that this protease has a preference for large hydrophobic residues in
P2 [11]. We observed a decrease in the Km value but virtually no
changes in the kcat value at 37 °C.
Next, we tested if we could detect substrate inhibition using natu-
ral TbbCATL. To this end, we prepared lysates from bloodstream form
T. brucei and ﬁrst, measured protease activity using a low Z-FR-MCA
concentration (Fig. 2A). The detected activity was largely inhibited
by E-64, indicating that we were measuring mainly papain-like prote-
ases in our assay conditions (Fig. 2A). Although we cannot discard the
contribution of the cathepsin B-like protease in the lysates, T. brucei
expresses large amounts of TbbCATL, which represents the main ac-
tivity in the lysates. We then performed hydrolysis curves of Z-FR-
MCA at 25 °C, and observed substrate inhibition, suggesting that the
activity of natural TbbCATL is also modulated at substrate concentra-
tions higher than 10 μM (Fig. 2B).
3.2. Temperature shifts quench the intrinsic tryptophan ﬂuorescence of
TbbCATL
Our data revealed that the susceptibility of recombinant TbbCATL
to substrate inhibition at 25 °C is partially reversible, i.e., it is absent
at 37 °C and is displayed when the same enzyme sample is assayed
again at 25 °C. We asked if temperature-induced conformational
changes occurred in TbbCATL at 37 °C, which in turn would prevent
the effect of high substrate concentrations on enzyme activity. We ex-
amined this by monitoring the change in intrinsic ﬂuorescence at the
two temperatures. The tryptophan ﬂuorescence spectra showed a de-
tectable shift when the enzyme was incubated at 37 °C, as compared
to 25 °C (Fig. 3A), resulting in a statistically signiﬁcant change in the
peak area of the spectra (Fig. 3B). Importantly, when subsequently
to the analysis of ﬂuorescence at 37 °C, the protease sample was re-
incubated at 25 °C, the spectra was similar to that of samples analysed
primarily at 25 °C. This result suggests that TbbCATL undergoes con-
formational changes when the temperature is shifted from 25 °C to
37 °C, and that those changes are reversible.
3.3. The activity of TbbCATL is modulated by heparan sulfate
Glycosaminoglycans bind to and modulate the activity of papa-
in, cathepsin B, cathepsin K and cathepsin X [31–34]. More recent-
ly, it was reported that heparin accelerates the inhibition of
cathepsin L by serpins due to the formation of ternary complexes
with the enzyme and the inhibitor [35]. We reported previously
that heparan sulfate (HS) decreases the afﬁnity of TcrCATL for
kininogen by 10-fold, up regulating the kinin-releasing activity
of the enzyme [36].
Next, we asked if HS could modulate the activity of TbbCATL. To
address this, we tested the inﬂuence of HS on the rate of hydrolysis
of Z-FR-MCA, at 25 °C, at two concentrations: i) 2.5 μM that is below
Vmax, ii) 50 μM, a concentration at which we observe substrate inhibi-
tion. HS (20 μg/mL) had no detectable effect on the rate of hydrolysis
of the substrate at 2.5 μM while it increased by 10-fold the rate of
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Fig. 1. Substrate inhibition of TbbCATL. Kinetics of substrate hydrolysis by recombinant TbbCATL assayed at 25 °C (A and C) or at 37 °C (B and D) with the indicated substrates. En-
zyme kinetics was performed in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM DTT, and product formation was monitored continuously in a ﬂuorimeter. The initial
velocities were calculated by linear regression of the plots of product concentration versus time. In B and D, the enzyme was pre-incubated at 37 °C for 15 min before the addition of
substrate and kept at 37 °C throughout the kinetics. The best calculated curves for the plots of initial velocities versus substrate concentrations were obtained by ﬁtting the exper-
imental data to the substrate inhibition (A) or Michaelis–Menten (B–D) equations. The experiments were performed independently at least three times.
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affecting substrate hydrolysis by rendering the enzyme less suscepti-
ble to substrate inhibition. Using a range of concentrations of HS, we
found a saturating effect on the increase in the initial velocity of the
enzyme at >1 μg/mL of HS, that is suggestive of the formation of an
enzyme–HS complex (Fig. 4B). The initial velocity for the hydrolysis
of Z-FR-MCA increases at higher HS concentrations, suggesting that
a potential enzyme–HS complex is less susceptible to substrate inhi-
bition. The ﬁtting of the experimental data to the equation to one
site-speciﬁc binding kinetics, resulted in a calculated dissociation
constant (Kd) of approximately 97 ng/mL. The analyses of the effect
of HS on substrate inhibition of TbbCATL showed that HS modiﬁes
slightly the susceptibility of the enzyme to substrate inhibition,
which is more evident as the concentration of HS reaches binding sat-
uration (Fig. 4C). Consistent with that, the Ki values for the substrate
increased in the presence of HS, while the Km decreased, suggesting
that HS decreases the afﬁnity of the allosteric substrate-binding site,
favoring substrate binding to the active site (Table 2). We furtherTable 1
Kinetic parameters for substrate hydrolysis by TbbCATL and for enzyme inactivation by
recombinant cysteine protease inhibitors.
Kinetic parameters for substrate hydrolysis
Ki
(μM)
Km
(μM)
kcat
(s−1)
kcat/Km
(mM−1s−1)
Z-FR-MCA
25 oC 52.41±12.32 0.46±0.11 0.52±0.08 1186.9±172.7
37 oC – 0.33±0.04 1.01±0.04 3148.4±134.5
Z-VLR-MCA
25 oC – 12.42±0.97 0.89±0.01 71.9±0.24
37 oC – 6.95±0.38 1.07±0.05 155.3±15.4veriﬁed the dose-dependence of HS on the enzyme susceptibility to
substrate inhibition by performing enzyme kinetics at 25 °C (Fig. 5).
We found that, at concentrations of HS of 10 μg/mL or higher,
TbbCATL displayed minimal susceptibility to substrate inhibition, in-
dicating that this glycosaminoglycan (GAG) prevents the allosteric ef-
fect of Z-FR-MCA on enzyme activity.
The analysis of the spectra of tryptophan ﬂuorescence of TbbCATL
in the presence of HS revealed no differences as compared to that of
the enzyme alone (data not shown), arguing against the induction
of HS-induced conformational alterations in the enzyme.
3.4. Degradation of ﬁbrinogen chains
Fibrinogen has been described as a protein substrate of lysosom-
al CPs of several trypanosomatids (T. brucei, T. congolense, T. vivax,
T. evansi, L. major, L. donovani) [37,38]. We analysed the proteolysis
of human ﬁbrinogen by recombinant TbbCATL in the presence or
absence of synthetic di-peptydyl substrates, in order to test if sub-
strate inhibition affects enzyme activity over protein substrates. To
this end, TbbCATL was incubated with ﬁbrinogen in the presence
or absence of Z-FR-MCA or Z-VLR-MCA, at 25 °C or at 37 °C
(Fig. 6). We observed efﬁcient degradation of the α and β chains
of ﬁbrinogen by TbbCATL at both temperatures (Fig. 6A and C,
lanes 3 and 4). However, ﬁbrinogen degradation was signiﬁcantly
impaired when the assays were carried out at 25 °C, in the presence
of Z-FR-MCA (Fig. 6A, lanes 7 and 8), but not in the presence of
Z-VLR-MCA (Fig. 6A, lanes 5 and 6), indicating that enzyme activity
was selectively impaired by Z-FR-MCA. In the presence of Z-FR-
MCA, the relative amounts of intact α and β ﬁbrinogen chains incu-
bated with TbbCATL were comparable to those of ﬁbrinogen alone
(Fig. 6B), conﬁrming that enzyme activity was signiﬁcantly down
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Fig. 2. Substrate inhibition of natural cysteine proteases of T. brucei. (A) Bloodstream form T. bruceiwas cultivated in vitro until stationary phase, washed and lysates were prepared
in 20 mMNa2HPO4, 150 mMNaCl, pH 7.2, 1% NP-40, on ice. The soluble material was tested for protease activity in 50 mMNa2HPO4, pH 6.5, 100 mMNaCl, 5 mM EDTA, 2.5 mM DTT
and Z-FR-MCA at the concentrations indicated in the ﬁgure. E-64 was used at 10 μM to conﬁrm that the activity detected in lysates corresponds to papain-like cysteine proteases.
The experiment was performed two independent times in duplicate. The plot of mean±SEM is representative of one experiment. (B) Kinetics of Z-FR-MCA hydrolysis by T. brucei
lysate assayed at 25 °C. The experiment was performed in duplicate, two independent times. The best calculated curves for the plots of initial velocities versus substrate concen-
trations were obtained by ﬁtting the experimental data to the substrate inhibition equation.
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fect of Z-FR-MCA over ﬁbrinogen degradation by TbbCATL was min-
imal, reﬂecting that, in the absence of substrate inhibition, TbbCATL
efﬁciently degrades the protein substrate.
4. Discussion
We investigated the kinetic behavior of TbbCATL (brucipain) to-
wards a couple of di-peptidyl ﬂuorogenic substrates, one of which,
Z-FR-MCA, is used often to study the potency and selectivity of syn-
thetic inhibitory compounds against this protease. We found that
TbbCATL undergoes strong substrate inhibition by Z-FR-MCA in the
micromolar range when assayed at 25 °C, a feature previouslyA
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Fig. 3. Effect of temperature on the ﬂuorescence emission spectra of TbbCATL. (A) The intrin
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incubated at 37 °C for 30 min, before recording the spectrum at 37 °C (red line). The same s
trum was recorded at 25 °C (gray line). Each experiment was performed independently thre
emission peak ranging from 300 to 390 nm were calculated for all experiments and the gra
ments. The statistical signiﬁcance was calculated using One-Way ANOVA.reported with T. cruzi TcrCATL [26,27]. The ﬁtting of our experimental
data was in agreement with the hypothesis that at concentrations
higher than 10 μM, the interaction of substrate molecules with re-
gions other than the active site renders the enzyme progressively in-
active. Those results suggest the presence of an allosteric site in the
central domain of TbbCATL, since the recombinant protease lacks
the C-terminal extension. A similar characteristic was described for
recombinant TcrCATL lacking the C-terminal extension [27], conﬁrm-
ing that those parasite proteases with similar structures are subject to
regulation through interactions with exposed regions of the central
domain. It was observed that cathepsin K undergoes substrate inhibi-
tion with Z-FR-MCA, Z-LR-MCA and Z-LLR-MCA at concentrations
above the Km [39], but only recently the molecular mechanismB
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Fig. 4. Effect of heparan sulfate on the substrate inhibition of TbbCATL. (A) TbbCATL was activated in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM DTT, for 10 min at
room temperature in the absence (white bars) or in the presence (black bars) of 20 μg/mL of heparan sulfate. The hydrolysis of Z-FR-MCA was monitored continuously at 25 °C, by
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498 T.F.R. Costa et al. / Biochimica et Biophysica Acta 1824 (2012) 493–501responsible for such events was elucidated [40]. It was reported that
cathepsin K ﬂuctuates between two main discrete conformations
that have different susceptibility to inhibition by Z-FR-MCA [40].
The conformational equilibrium is regulated by ionic strength and
the dominant conformational state at high salt is more susceptible
to inhibition by this substrate. At low substrate concentration, a re-
equilibration of the conformational states of the enzyme occurs, and
the substrate-bound form adopts a conformation that is more suscep-
tible to substrate inhibition. The different susceptibility of TbbCATL to
substrate inhibition at 25 °C versus 37 °C is reminiscent of the behav-
ior described for cathepsin K at different ionic strengths, suggesting
that at 37 °C, the enzyme adopts a conformation less favorable to
the binding of substrate at the allosteric site.
Allostery is a common regulation process that is based on the
modulation of a protein behavior, where a change in one site affects
the function of a second distant site [41]. Although the allosteric reg-
ulation of papain-like enzymes was not investigated at the structural
level, the allosteric regulation of the Clan CD cysteine protease
of Clostridium difﬁcile, CPD, has been well-characterized. CPD is
activated through allosteric regulation by interactions with inositolTable 2
Effect of heparan sulfate on the kinetic parameters for the hydrolysis of Z-FR-MCA by
recombinant TbbCATL at 25 oC.
Z-Phe-Arg-
MCA (25 oC)
Ki
(μM)
Km
(μM)
kcat
(s−1)
kcat/Km
(mM−1s−1)
Heparan
sulfate (μg/mL)
1 99.19±14.93 0.44±0.05 0.52±0.03 1119.4±25.4
5 331.7±119.1 0.41±0.05 0.46±0.01 1121.4±135.3
10 – 0.37±0.03 0.39±0.01 1087.5±17.9
20 – 0.47±0.05 0.43±0.01 999.8±96.5hexakisphosphate (InsP6), which binds to a basic cleft that is distinct
from the active site, resulting in conformational changes that are
linked to protease activation [42]. More recently, it was shown that
InsP6 binds to a positively charged cleft that is distal from the active
site, and an anti-parallel β-hairpin structure appears to bridge the
InsP6 and substrate-binding pockets [43]. Considering that the
active-site cleft of TbbCATL is buried in the inter-domain interface
and can only accommodate one substrate molecule, it is reasonable
to assume that excess Z-FR-MCA acts through binding in sites distant
from the active site, inducing conformational changes that alter the
functionality of the active site.
Strong substrate inhibition was evident at 25 °C but undetectable
at 37 °C, indicating that the secondary substrate-biding site is avail-
able for binding at 25 °C, while it is concealed at 37 °C. Importantly,
we observed shifts in the ﬂuorescence emission spectra of the en-
zyme at those temperatures, suggesting the occurrence of conforma-
tional changes that have an impact on the enzyme susceptibility to
substrate inhibition, i.e., on the availability of the allosteric site. The
reversibility of such conformational changes favors the hypothesis
of a mechanism of regulation through the controlled and inter-
changeable exposure of an allosteric site. We found no substrate inhi-
bition with Z-VLR-MCA, indicating that the putative allosteric site
discriminates between bulky and small hydrophobic residues. At pre-
sent, we do not know how the binding of a second substrate molecule
exerts its effect on the active site, but it is possible that it induces local
perturbations in the enzyme's structure that have an important effect
in enzyme's sub-sites.
The potential signiﬁcance of this ﬁnding is that TbbCATL activity is
subject to a transitory and reversible down regulation through the
binding of compounds to an allosteric site. Although not addressed
here, several molecules with bulky hydrophobic residues present in
the invertebrate or mammalian hosts are candidates for allosteric
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and, at high concentrations, negatively regulates the activity of an
aspartic protease from the eggs of Boophilus microplus, illustrating
how natural occurring small hydrophobic molecules have the poten-
tial to regulate protease activity through allostery [44]. The modula-
tion of the peptidolytic activity of TbbCATL by host molecules by
means of controlled proteolysis could favor the generation ofA
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Fig. 6. Allosteric modulation by Z-FR-MCA prevents the proteolysis of human ﬁbrinogen by
ﬁbrinogen (Fbg) in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 0.5 mM DTT, for 15 m
in the presence of 60 μM of Z-VLR-MCA or Z-FR-MCA. In C and D, TbbCATL was incubated at
as indicated at the top of each lane. Control ﬁbrinogen was kept in the same conditions, in th
ple buffer under reducing conditions, separated by electrophoresis and Coomassie stained. T
by densitometry using ImageJ and the average DO±SEM is shown in (B) 25 °C, and (D) 37
asterisk indicates signiﬁcance at pb0.05 and double asterisks indicate signiﬁcance from conbiologically active peptides. Control of enzyme activity might be rele-
vant in face of the shifts in temperature encountered by T. brucei
when changing from the invertebrate to the mammalian host.
We found a signiﬁcant effect of HS on enzyme activity and on its
susceptibility to substrate inhibition. This effect could be mediated
through the formation of an enzyme–HS complex that reaches satura-
tion at lowmicromolar concentrations of HS or by a shielding effect ofB
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trol at pb0.001.
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of the enzyme ﬂuorescence spectra in the presence of HS, contrary
to that observed during the shifts in temperature, suggesting that
this GAG might interfere by interacting directly with the allosteric
site of the enzyme. Although we have not mapped putative interac-
tion sites of TbbCATL with HS, such regions have been reported for
other papain-like enzymes. Recently, an in silico docking study
mapped two putative binding sites for heparin on catB, located in
positive patches at exposed regions of the left and the right domain
[45]. It was observed that the allosteric effect of heparin binding
resulted from the rearrangement of contacts between catB domains,
favoring the maintenance of helical content as well as active-site sta-
bility. It is possible that a putative HS biding site(s) in TbbCATL is in
proximity to the allosteric site, preventing its interaction with sub-
strate molecules and thus affecting substrate inhibition. Alternatively,
HS might exert its effect in a similar manner to that in cathepsin B, i.e.,
by a long-distance allosteric mechanism. Since HS is commonly found
associated with the endothelium, it might serve as an anchoring site
for TbbCATL released from dying parasites in the circulation. It re-
mains to be determined if the interaction with HS can shield the en-
zyme from inhibition by serum inhibitors.
Finally, we showed that the allosteric regulation of TbbCATL by Z-
FR-MCA prevents the degradation of a potential natural substrate, ﬁ-
brinogen. The proteolysis of ﬁbrinogen by lysosomal papain-like pro-
teases of T. brucei, has been reported [38] and it was described that
antibodies to ﬁbrinogen/ﬁbrin related products was observed in rats
experimentally infected with T. brucei [46], suggesting that some
level of ﬁbrinogen processing occurs during infection. Since the bind-
ing of ﬁbrinogen to its receptor at the surface of platelets is essential
for aggregation responses [47], ﬁbrinogen processing by a parasite
protease might inﬂuence blood coagulation during infection, contrib-
uting to disease pathology. The lack of effect of Z-VLR-MCA on ﬁbrin-
ogen degradation excludes the possibility that the diminished
proteolysis observed in the presence of Z-FR-MCA was caused by
strong active-site competition with the di-peptydyl substrate. More-
over, Z-FR-MCA had minimal effect on ﬁbrinogen degradation by
TbbCATL in assays performed at 37 °C, favoring the hypothesis that
at 25 °C the binding of this substrate to the allosteric site renders
TbbCATL inactive towards protein substrates. We propose that
TbbCATL can shift between an open (active) and closed (inactive,
with regards to protein substrates) conformation as a result of inter-
actions through an allosteric site present in the central domain. The
existence of conformational ﬂexibility and allosteric regulation of cys-
teine cathepsins are emerging concepts. The occurrence of such
mechanism to control the activity of parasite-derived proteases
opens new possibilities for regulated proteolysis as an adaptation to
the hosts.Acknowledgements
We thank Angela Alves and Rozenita S. P. Azevedo for technical as-
sistance. This work was supported by CNPq and FAPERJ. APCAL is a
CNPq fellow.References
[1] D. Steverding, The history of African trypanosomiasis, Parasit Vectors 1 (2008) 3.
[2] P.G. Kennedy, The continuing problem of human African trypanosomiasis (sleep-
ing sickness), Ann. Neurol. 64 (2008) 116–126.
[3] C.R. Caffrey, D. Steverding, Kinetoplastid papain-like cysteine proteases, Mol. Bio-
chem. Parasitol. 167 (2009) 12–19.
[4] R. Brun, J. Blum, F. Chappuis, C. Burri, Human African trypanosomiasis, Lancet 375
(2010) 148–159.
[5] A. Luscher, H.P. de Koning, P. Maser, Chemotherapeutic strategies against Trypano-
soma brucei: drug targets vs. drug targeting, Curr. Pharm. Des. 13 (2007) 555–567.
[6] L. Troeberg, X. Chen, T.M. Flaherty, R.E. Morty, M. Cheng, H. Hua, C. Springer, J.H.
McKerrow, G.L. Kenyon, J.D. Lonsdale-Eccles, T.H. Coetzer, F.E. Cohen, Chalcone,acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei, Mol.
Med. 6 (2000) 660–669.
[7] S. Scory, C.R. Caffrey, Y.D. Stierhof, A. Ruppel, D. Steverding, Trypanosoma brucei:
killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhib-
itor Z-phe-ala-CHN2, Exp. Parasitol. 91 (1999) 327–333.
[8] S. Scory, Y.D. Stierhof, C.R. Caffrey, D. Steverding, The cysteine proteinase inhibi-
tor Z-Phe-Ala-CHN2 alters cell morphology and cell division activity of Trypano-
soma brucei bloodstream forms in vivo, Kinetoplastid Biol. Dis. 6 (2007) 2.
[9] J.D. Lonsdale-Eccles, D.J. Grab, Lysosomal and non-lysosomal peptidyl hydrolases
of the bloodstream forms of Trypanosoma brucei brucei, Eur. J. Biochem. 169
(1987) 467–475.
[10] C.D. Robertson, M.J. North, B.C. Lockwood, G.H. Coombs, Analysis of the protein-
ases of Trypanosoma brucei, J. Gen. Microbiol. 136 (1990) 921–925.
[11] C.R. Caffrey, E. Hansell, K.D. Lucas, L.S. Brinen, A. Alvarez Hernandez, J. Cheng, S.L.
Gwaltney II, W.R. Roush, Y.D. Stierhof, M. Bogyo, D. Steverding, J.H. McKerrow,
Active site mapping, biochemical properties and subcellular localization of rhode-
sain, the major cysteine protease of Trypanosoma brucei rhodesiense, Mol. Bio-
chem. Parasitol. 118 (2001) 61–73.
[12] M. Berriman, E. Ghedin, C. Hertz-Fowler, G. Blandin, H. Renauld, D.C. Bartholomeu,
N.J. Lennard, E. Caler, N.E. Hamlin, B. Haas, U. Bohme, L. Hannick, M.A. Aslett, J.
Shallom, L. Marcello, L. Hou, B. Wickstead, U.C. Alsmark, C. Arrowsmith, R.J.
Atkin, A.J. Barron, F. Bringaud, K. Brooks, M. Carrington, I. Cherevach, T.J.
Chillingworth, C. Churcher, L.N. Clark, C.H. Corton, A. Cronin, R.M. Davies, J.
Doggett, A. Djikeng, T. Feldblyum, M.C. Field, A. Fraser, I. Goodhead, Z. Hance,
D. Harper, B.R. Harris, H. Hauser, J. Hostetler, A. Ivens, K. Jagels, D. Johnson, J.
Johnson, K. Jones, A.X. Kerhornou, H. Koo, N. Larke, S. Landfear, C. Larkin, V.
Leech, A. Line, A. Lord, A. Macleod, P.J. Mooney, S. Moule, D.M. Martin, G.W.
Morgan, K. Mungall, H. Norbertczak, D. Ormond, G. Pai, C.S. Peacock, J. Peterson,
M.A. Quail, E. Rabbinowitsch, M.A. Rajandream, C. Reitter, S.L. Salzberg, M.
Sanders, S. Schobel, S. Sharp, M. Simmonds, A.J. Simpson, L. Tallon, C.M. Turner,
A. Tait, A.R. Tivey, S. Van Aken, D. Walker, D. Wanless, S. Wang, B. White, O.
White, S. Whitehead, J. Woodward, J. Wortman, M.D. Adams, T.M. Embley, K.
Gull, E. Ullu, J.D. Barry, A.H. Fairlamb, F. Opperdoes, B.G. Barrell, J.E. Donelson,
N. Hall, C.M. Fraser, S.E. Melville, N.M. El-Sayed, The genome of the African
trypanosome Trypanosoma brucei, Science 309 (2005) 416–422.
[13] J.C. Mottram, M.J. North, J.D. Barry, G.H. Coombs, A cysteine proteinase cDNA from
Trypanosoma brucei predicts an enzyme with an unusual C-terminal extension,
FEBS Lett. 258 (1989) 211–215.
[14] O.V. Nikolskaia, A.P. de A.L., Y.V. Kim, J.D. Lonsdale-Eccles, T. Fukuma, J. Scharfstein,
D.J. Grab, Blood-brain barrier traversal by African trypanosomes requires calcium
signaling induced by parasite cysteine protease, J. Clin. Invest. 116 (2006)
2739–2747.
[15] M.H. Abdulla, T. O'Brien, Z.B. Mackey, M. Sajid, D.J. Grab, J.H. McKerrow, RNA in-
terference of Trypanosoma brucei cathepsin B and L affects disease progression
in a mouse model, PLoS Negl. Trop. Dis. 2 (2008) e298.
[16] X. Du, E. Hansell, J.C. Engel, C.R. Caffrey, F.E. Cohen, J.H. McKerrow, Aryl ureas rep-
resent a new class of anti-trypanosomal agents, Chem. Biol. 7 (2000) 733–742.
[17] C. Bryant, I.D. Kerr, M. Debnath, K.K. Ang, J. Ratnam, R.S. Ferreira, P. Jaishankar, D.
Zhao, M.R. Arkin, J.H. McKerrow, L.S. Brinen, A.R. Renslo, Novel non-peptidic
vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases,
Bioorg. Med. Chem. Lett. 19 (2009) 6218–6221.
[18] P. Jaishankar, E. Hansell, D.M. Zhao, P.S. Doyle, J.H. McKerrow, A.R. Renslo, Poten-
cy and selectivity of P2/P3-modiﬁed inhibitors of cysteine proteases from try-
panosomes, Bioorg. Med. Chem. Lett. 18 (2008) 624–628.
[19] W.R. Roush, J. Cheng, B. Knapp-Reed, A. Alvarez-Hernandez, J.H.McKerrow, E. Hansell,
J.C. Engel, Potent second generation vinyl sulfonamide inhibitors of the trypanosomal
cysteine protease cruzain, Bioorg. Med. Chem. Lett. 11 (2001) 2759–2762.
[20] J.P. Mallari, A. Shelat, A. Kosinski, C.R. Caffrey, M. Connelly, F. Zhu, J.H. McKerrow,
R.K. Guy, Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain
and TbcatB, Bioorg. Med. Chem. Lett. 18 (2008) 2883–2885.
[21] J.P. Mallari, A.A. Shelat, T. Obrien, C.R. Caffrey, A. Kosinski, M. Connelly, M. Harbut,
D. Greenbaum, J.H. McKerrow, R.K. Guy, Development of potent purine-derived
nitrile inhibitors of the trypanosomal protease TbcatB, J. Med. Chem. 51 (2008)
545–552.
[22] R. Ettari, M. Zappala, N. Micale, T. Schirmeister, C. Gelhaus, M. Leippe, A. Evers, S.
Grasso, Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine
proteases falcipain-2 and rhodesain, Eur. J. Med. Chem. 45 (2010) 3228–3233.
[23] I.D. Kerr, J.H. Lee, C.J. Farady, R. Marion, M. Rickert, M. Sajid, K.C. Pandey, C.R.
Caffrey, J. Legac, E. Hansell, J.H. McKerrow, C.S. Craik, P.J. Rosenthal, L.S. Brinen,
Vinyl sulfones as antiparasitic agents and a structural basis for drug design, J.
Biol. Chem. 284 (2009) 25697–25703.
[24] I.D. Kerr, P. Wu, R. Marion-Tsukamaki, Z.B. Mackey, L.S. Brinen, Crystal structures
of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine
proteases of Trypanosoma brucei, PLoS Negl. Trop. Dis. 4 (2010) e701.
[25] D.N. Gosalia, C.M. Salisbury, J.A. Ellman, S.L. Diamond, High throughput substrate
speciﬁcity proﬁling of serine and cysteine proteases using solution-phase ﬂuoro-
genic peptide microarrays, Mol. Cell Proteomics 4 (2005) 626–636.
[26] A.P. Lima, J. Scharfstein, A.C. Storer, R. Menard, Temperature-dependent substrate
inhibition of the cysteine proteinase (GP57/51) from Trypanosoma cruzi, Mol. Bio-
chem. Parasitol. 56 (1992) 335–338.
[27] V. Stoka, J.H. McKerrow, J.J. Cazzulo, V. Turk, Substrate inhibition of cruzipain is
not affected by the C-terminal domain, FEBS Lett. 429 (1998) 129–133.
[28] F.C. Reis, T.F. Costa, T. Sulea, A. Mezzetti, J. Scharfstein, D. Bromme, R. Menard, A.P.
Lima, The propeptide of cruzipain—a potent selective inhibitor of the trypanoso-
mal enzymes cruzipain and brucipain, and of the human enzyme cathepsin F,
FEBS J. 274 (2007) 1224–1234.
501T.F.R. Costa et al. / Biochimica et Biophysica Acta 1824 (2012) 493–501[29] A.P. Lima, F.C. dos Reis, C. Serveau, G. Lalmanach, L. Juliano, R. Menard, T. Vernet,
D.Y. Thomas, A.C. Storer, J. Scharfstein, Cysteine protease isoforms from Trypano-
soma cruzi, cruzipain 2 and cruzain, present different substrate preference and
susceptibility to inhibitors, Mol. Biochem. Parasitol. 114 (2001) 41–52.
[30] S.M. Smith, M.M. Gottesman, Activity and deletion analysis of recombinant
human cathepsin L expressed in Escherichia coli, J. Biol. Chem. 264 (1989)
20487–20495.
[31] P.C. Almeida, I.L. Nantes, J.R. Chagas, C.C. Rizzi, A. Faljoni-Alario, E. Carmona, L.
Juliano, H.B. Nader, I.L. Tersariol, Cathepsin B activity regulation. Heparin-like gly-
cosaminogylcans protect human cathepsin B from alkaline pH-induced inactiva-
tion, J. Biol. Chem. 276 (2001) 944–951.
[32] P.C. Almeida, I.L. Nantes, C.C. Rizzi, W.A. Judice, J.R. Chagas, L. Juliano, H.B. Nader,
I.L. Tersariol, Cysteine proteinase activity regulation. A possible role of heparin
and heparin-like glycosaminoglycans, J. Biol. Chem. 274 (1999) 30433–30438.
[33] Z. Li, Y. Yasuda, W. Li, M. Bogyo, N. Katz, R.E. Gordon, G.B. Fields, D. Bromme, Reg-
ulation of collagenase activities of human cathepsins by glycosaminoglycans, J.
Biol. Chem. 279 (2004) 5470–5479.
[34] F.D. Nascimento, C.C. Rizzi, I.L. Nantes, I. Stefe, B. Turk, A.K. Carmona, H.B. Nader, L.
Juliano, I.L. Tersariol, Cathepsin X binds to cell surface heparan sulfate proteogly-
cans, Arch. Biochem. Biophys. 436 (2005) 323–332.
[35] W.J. Higgins, D.M. Fox, P.S. Kowalski, J.E. Nielsen, D.M. Worrall, Heparin enhances
serpin inhibition of the cysteine protease cathepsin L, J. Biol. Chem. 285 (2010)
3722–3729.
[36] A.P. Lima, P.C. Almeida, I.L. Tersariol, V. Schmitz, A.H. Schmaier, L. Juliano, I.Y.
Hirata, W. Muller-Esterl, J.R. Chagas, J. Scharfstein, Heparan sulfate modulates
kinin release by Trypanosoma cruzi through the activity of cruzipain, J. Biol.
Chem. 277 (2002) 5875–5881.
[37] J.D. Lonsdale-Eccles, G.W.Mpimbaza, Thiol-dependent proteases of African trypano-
somes. Analysis by electrophoresis in sodium dodecyl sulphate/polyacrylamide gels
co-polymerized with ﬁbrinogen, Eur. J. Biochem. 155 (1986) 469–473.[38] J.D. Lonsdale-Eccles, G.W. Mpimbaza, Z.R. Nkhungulu, J. Olobo, L. Smith, O.M.
Tosomba, D.J. Grab, Trypanosomatid cysteine protease activity may be enhanced
by a kininogen-like moiety from host serum, Biochem. J. 305 (Pt 2) (1995)
549–556.
[39] M.J. Bossard, T.A. Tomaszek, S.K. Thompson, B.Y. Amegadzie, C.R. Hanning, C.
Jones, J.T. Kurdyla, D.E. McNulty, F.H. Drake, M. Gowen, M.A. Levy, Proteolytic ac-
tivity of human osteoclast cathepsin K. Expression, puriﬁcation, activation, and
substrate identiﬁcation, J. Biol. Chem. 271 (1996) 12517–12524.
[40] M. Novinec, L. Kovacic, B. Lenarcic, A. Baici, Conformational ﬂexibility and alloste-
ric regulation of cathepsin K, Biochem. J. 429 (2010) 379–389.
[41] J.P. Changeux, S.J. Edelstein, Allosteric mechanisms of signal transduction, Science
308 (2005) 1424–1428.
[42] R.N. Pruitt, B. Chagot, M. Cover, W.J. Chazin, B. Spiller, D.B. Lacy, Structure–function
analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difﬁ-
cile toxin A, J. Biol. Chem. 284 (2009) 21934–21940.
[43] A. Shen, P.J. Lupardus, M.M. Gersch, A.W. Puri, V.E. Albrow, K.C. Garcia, M. Bogyo,
Deﬁning an allosteric circuit in the cysteine protease domain of Clostridium difﬁ-
cile toxins, Nat. Struct. Mol. Biol. 18 (2011) 364–371.
[44] M.H. Sorgine, C. Logullo, R.B. Zingali, G.O. Paiva-Silva, L. Juliano, P.L. Oliveira, A
heme-binding aspartic proteinase from the eggs of the hard tick Boophilus micro-
plus, J. Biol. Chem. 275 (2000) 28659–28665.
[45] M.G. Costa, P.R. Batista, C.S. Shida, C.H. Robert, P.M. Bisch, P.G. Pascutti, How does
heparin prevent the pH inactivation of cathepsin B? Allosteric mechanism eluci-
dated by docking and molecular dynamics, BMC Genomics 11 (Suppl 5) (2010)
S5.
[46] W.J. Rickman, H.W. Cox, Immunologic reactions associated with anemia, throm-
bocytopenia, and coagulopathy in experimental African trypanosomiasis, J. Parasi-
tol. 66 (1980) 28–33.
[47] J. Rivera, M.L. Lozano, L. Navarro-Nunez, V. Vicente, Platelet receptors and signal-
ing in the dynamics of thrombus formation, Haematologica 94 (2009) 700–711.
